Bupivacaine is under clinical development by Allay Therapeutics and currently in Phase II for Post-Operative Pain. According to GlobalData, Phase II drugs for Post-Operative Pain have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bupivacaine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bupivacaine overview

Bupivacaine (ATX-101) is under development for the treatment of pain due to total knee replacement surgery. It is administered in the form of implant. It acts as sodium ion channel blocker.

Allay Therapeutics overview

Allay Therapeutics is a biotechnology company focusing on analgesic products to transform post-surgical pain management and recuperation for patients and physicians. Allay Therapeutics is headquartered in Menlo Park, California, the US.

For a complete picture of Bupivacaine’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.